TES-1025 是一种有效的和选择性人 α-氨基-β-羧基粘康酸-ε-半醛脱羧酶 (ACMSD) 抑制剂，IC₅₀ 为 13 nM。

TES-1025 is a potent and selective human α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) inhibitor with an IC 50 of 13 nM.

Solid

IC50: 13±3 nM (human ACMSD)

TES-1025 is a low nanomolar human ACMSD inhibitor, which increases NAD levels in cellular systems. has not independently confirmed the accuracy of these methods. They are for reference only.

TES-1025 is subjected to in vivo pharmacokinetic studies, following intravenous (IV) and oral (PO) dosings of male CD-1 mice. After the intravenous administration of 0.5 mg/kg, TES-1025 shows low blood clearance, with low volumes of distribution and half-lives (t 1/2 ) of about 5.33 h, although after oral administration at 5 mg/kg, the blood concentration of TES-1025 is quantifiable for up to 8 h. A good systemic exposure is recorded for TES-1025, with a C max of 2570 ng/mL reaches at 2 h after dosing. The greater oral exposure of TES-1025 is further confirmed in the liver and kidneys with AUC 0-8h of 19?200 h?ng/mL and 36?600 h?ng/mL, respectively. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Pellicciari R, et al. α-Amino-β-carboxymuconate-ε-semialdehyde Decarboxylase (ACMSD) Inhibitors as Novel Modulators of De Novo Nicotinamide Adenine Dinucleotide (NAD+) Biosynthesis. J Med Chem. 2018 Feb 8;61(3):745-759.

In Vitro: DMSO : 100 mg/mL (260.80 mM; Need warming)配制储备液